A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 30
- 试验地点
- 13
- 主要终点
- Maximally tolerated dose (MTD) of cixitumumab when administered in a combination regimen with fixed dose doxorubicin hydrochloride, in patients with locally advanced or metastatic soft tissue sarcoma
研究概览
简要总结
This phase I trial is studying the side effects and best dose of cixutumumab given together with doxorubicin hydrochloride and to see how well they work in treating patients with unresectable, locally advanced, or metastatic soft tissue sarcoma. Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving monoclonal antibody cixutumumab together with doxorubicin hydrochloride may kill more tumor cells.
详细描述
PRIMARY OBJECTIVES:
I. To collect safety data about the combination of doxorubicin and Cixitumumab and determine if they can be combined with acceptable toxicity at full doses.
SECONDARY OBJECTIVES:
I. To assess the confirmed response rate (CR + PR as defined by RECIST) of patients with locally advanced or metastatic soft tissue sarcoma when treated with combination doxorubicin and Cixitumumab II. To assess the 3 and 6 month progression free survival rate of patients treated with doxorubicin and Cixitumumab.
III. To assess the progression free survival and overall survival of patients treated with doxorubicin and Cixitumumab.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 16 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically confirmed soft tissue sarcoma
- •Unresectable disease
- •Locally advanced or metastatic disease
- •The following tumor types are not allowed:
- •Embryonal and alveolar rhabdomyosarcoma
- •Gastrointestinal stromal tumor
- •Alveolar soft part sarcoma
- •Clear cell sarcoma
- •Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques or ≥ 10 mm by spiral CT scan
- •No more than 1 prior therapy for sarcoma
- •No known brain metastases
- •ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100%
- •ANC ≥ 1,500/µL
- •Platelet count ≥ 100,000/µL
- •Leukocytes ≥ 3,000/µL
- •Total bilirubin ≤ upper limit of normal(ULN)
- •AST and ALT ≤ 2.5 times ULN
- •Creatinine ≤ 1.5 times ULN OR creatinine clearance ≥ 60 mL/min
- •Fasting serum glucose < 120 mg/dL OR below ULN
- •LVEF ≥ 50% by MUGA scan
- •Not pregnant or nursing
- •Negative pregnancy test
- •Fertile patients must use effective contraception during and for 3 months after the last dose of anti-IGF-1R recombinant monoclonal antibody IMC-A12
- •No history of allergic reactions attributed to compounds of similar chemical or biological composition to anti-IGF-1R recombinant monoclonal antibody IMC-A12
- •No poorly controlled diabetes mellitus
- •Patients with a history of diabetes mellitus are eligible provided their blood glucose is within normal range and they are on a stable dietary or therapeutic regimen for this condition
- •No concurrent uncontrolled illness including, but not limited to, any of the following:
- •Ongoing or active infection
- •Symptomatic congestive heart failure
- •Unstable angina pectoris
- •Cardiac arrhythmia
- •Psychiatric illness or social situation that would preclude compliance with study requirements
- •No other concurrent investigational or commercial agents or therapies
- •Recovered from all prior therapy
- •More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C)
- •More than 4 weeks since prior major surgery, hormonal therapy (other than replacement), or hormonal therapy
- •No prior radiotherapy to the heart, mediastinum, or chest wall
- •No prior anthracycline therapy or anti-IGF-1R therapy
排除标准
- 未提供
研究组 & 干预措施
Treatment (cixutumumab and doxorubicin hydrochloride)
Patients receive cixutumumab IV over 1 hour on days 1, 8, and 15 and doxorubicin hydrochloride IV continuously over 44-52 hours beginning on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease may continue to receive cixutumumab in the absence of disease progression or unacceptable toxicity.
干预措施: Cixutumumab (Biological)
Treatment (cixutumumab and doxorubicin hydrochloride)
Patients receive cixutumumab IV over 1 hour on days 1, 8, and 15 and doxorubicin hydrochloride IV continuously over 44-52 hours beginning on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease may continue to receive cixutumumab in the absence of disease progression or unacceptable toxicity.
干预措施: Doxorubicin Hydrochloride (Drug)
Treatment (cixutumumab and doxorubicin hydrochloride)
Patients receive cixutumumab IV over 1 hour on days 1, 8, and 15 and doxorubicin hydrochloride IV continuously over 44-52 hours beginning on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease may continue to receive cixutumumab in the absence of disease progression or unacceptable toxicity.
干预措施: Laboratory Biomarker Analysis (Other)
结局指标
主要结局
Maximally tolerated dose (MTD) of cixitumumab when administered in a combination regimen with fixed dose doxorubicin hydrochloride, in patients with locally advanced or metastatic soft tissue sarcoma
时间窗: Up to 2 courses of treatment
The MTD is defined as the dose of Cixitumumab that induces dose-limiting toxicity (DLT) in no more than 20% of patients.
次要结局
- Changes in cardiac function as measured by MUGA scans of the left ventricular ejection fraction(Baseline to 6 courses of treatment)
- Confirmed response rate (CR + PR) for comparison with doxorubicin treatment in similar historical patient populations(Up to 6 months)
- Overall survival(Until death due to any cause, or loss to follow-up, assessed up to 6 months)
- Progression-free survival(Until documented disease progression or death or loss-to-follow-up, assessed up to 6 months)